Article Text

Download PDFPDF
HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis
  1. Yukinori Okada1,2,
  2. Akari Suzuki3,
  3. Ryo Yamada2,
  4. Yuta Kochi3,
  5. Kenichi Shimane1,3,
  6. Keiko Myouzen3,
  7. Michiaki Kubo4,
  8. Yusuke Nakamura5,
  9. Kazuhiko Yamamoto1,3
  1. 1Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
  2. 2Laboratory of Functional Genomics, Human Genome Center, Institute of Medical Science, University of Tokyo (HGC, IMS-UT), Tokyo, Japan
  3. 3Laboratory for Autoimmune Diseases, Center for Genomic Medicine, Institute of Physical and Chemical Research (CGM, RIKEN), Yokohama, Japan
  4. 4Laboratory for Genotyping Development, CGM, RIKEN, Yokohama, Japan
  5. 5Laboratory of Molecular Medicine, HGC, IMS-UT, Tokyo, Japan
  1. Correspondence to Dr Y Okada, Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; yokada-tky{at}

Statistics from

Anti-cyclic citrullinated peptide (anti-CCP) antibody is a highly specific biomarker for rheumatoid arthritis (RA), and is recognised as a predictor of the development of RA.1 2 It has been demonstrated that some HLA-DRB1 alleles, such as shared epitope (SE) alleles, significantly contribute to the positivity of anti-CCP antibody and the susceptibility of anti-CCP antibody-positive RA.3 4 However, the quantitative effect of HLA-DRB1 alleles on anti-CCP antibody levels in RA patients is controversial.3 5 6 Therefore, we carried out a large-scale study to study the quantitative effects of HLA-DRB1 alleles on anti-CCP antibody levels in Japanese patients with RA.

A total of 2384 Japanese patients with RA was recruited through several medical institutes of Japan under the support of the BioBank Japan Project7 (age 61.5±11.8 years (mean±SD), 81.2% were women). All patients fulfilled the American College of Rheumatology revised criteria for RA, and provided written informed consent. Serum anti-CCP antibody levels were assayed using the second-generation anti-CCP ELISA kit (DIASTAT Anti-CCP; MBL, Nagoya, Japan) with …

View Full Text


  • The first two authors contributed equally.

  • Funding This study was supported by a grant from CGM, RIKEN and a grant for Research on Intractable Diseases and Research on Human Genome Tailor-Made from the Ministry of Health, Labour and Welfare of Japan.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Approved by the Ethical Committee of the BioBank Japan Project.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.